Assessment of the Bordetella pertussis BpCNIC0311 Strain as a Producing Strain of Genetically Detoxified Toxoid (PTg), Filamentous Hemagglutinin (FHA) and Type 2 Pertactin (Prn2)
Diógenes Quintana‐Vázquez(Centro de Ingeniería Genética y Biotecnología), Anabel Álvarez(Centro de Ingeniería Genética y Biotecnología), Yassel Ramos(Centro de Ingeniería Genética y Biotecnología), Gerardo Guillén(Hunan City University), Edelgis Coizeau(Centro de Ingeniería Genética y Biotecnología), Gilda Lemos(Centro de Ingeniería Genética y Biotecnología), Yanet Támbara(National Center for Genetic Engineering and Biotechnology), Luis Javier Gonzales(National Center for Genetic Engineering and Biotechnology), Maité Delgado
Cited by 1
Related Papers
Epidermal growth factor in clinical practice – a review of its biological actions, clinical indications and safety implications
|International Wound Journal|2009|167
A novel cancer vaccine composed of human-recombinant epidermal growth factor linked to a carrier protein: Report of a pilot clinical trial
|Annals of Oncology|1998|155
Glucose Toxic Effects on Granulation Tissue Productive Cells: The Diabetics’ Impaired Healing
|BioMed Research International|2012|153
Wound Chronicity, Impaired Immunity and Infection in Diabetic Patients
|MEDICC Review|2021|139
Insulin Resistance at the Crossroad of Alzheimer Disease Pathology: A Review
|Frontiers in Endocrinology|2020|134